New Delhi, Nov. 5 -- Solara Active Pharma Sciences Limited has reported its financial results for the second quarter of the fiscal year 2026, highlighting a period marked by short-term operational disruptions but underscored by strong long-term fundamentals.

The company, which is listed on both the BSE and NSE, disclosed a decline in revenue and profitability due to an unscheduled operational shutdown at its Mangalore facility, according to an exchange filing dated November 5, 2025.

The pharmaceutical company reported a revenue of Rs.3,140 million for Q2 FY26, a 10% decrease from Rs.3,472 million in the same quarter of the previous year. The quarter-on-quarter comparison also showed a slight decline of 2% from Rs.3,201 million in Q1 FY2...